New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:22 EDTAVXT, GNBT, ARGS, GALE, LBIOMaidstone Life Sciences to hold a conference
4th Annual Cancer Immunotherapy: A Long Awaited Reality Conference is being held in New York on March 27.
News For LBIO;ARGS;AVXT;GALE;GNBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
09:17 EDTGALEOn The Fly: Pre-market Movers
Subscribe for More Information
November 20, 2014
16:22 EDTGALEGalena announces $55M purchase agreement with Lincoln Park Capital
Galena Biopharma announced the execution of a purchase agreement for up to $55M with Lincoln Park Capital Fund, a Chicago-based institutional investor. Under the terms of the purchase agreement dated November 18, LPC initially purchased $5M of Galena common stock at a price of $2.00 per share, 9% higher than the market close as of November 18, 2014. Thereafter, at its sole discretion, Galena may sell up to $50M worth of common stock to LPC over the 36-month term of the purchase agreement, subject to the conditions and limitations set forth in the purchase agreement. Under the terms of the purchase agreement, LPC will not cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Galena common stock and is obligated to purchase at times and amounts controlled by the company. In consideration for entering into the agreement the company issued shares of its common stock to LPC as a commitment fee. Galena plans to use the proceeds received for its commercial and product development activities and for other working capital and general corporate purposes.
November 18, 2014
09:32 EDTGNBTGenerex Biotech announces collaboration on medicinal cannabis
Generex Biotechnology announced that it has entered into a non-binding Letter of Intent to license the company's proprietary RapidMist drug delivery technologies to CannScience Innovations for the delivery of medicinal cannabis derived products into the bloodstream through the buccal membrane. This co-development arrangement with CannScience is intended to develop products initially for the Canadian medical cannabis market. The LOI contemplates a significant royalty stream to Generex. Costs to develop, manufacture, and commercialize the products will be borne by CannScience. Further, products developed through this co-development arrangement may potentially be commercialized in international markets.
07:37 EDTGALEStifel to hold a conference
Subscribe for More Information
07:09 EDTGALEGalena completes enrollment in GALE-401 Phase 2 clinical trial
Galena Biopharma announced the completion of enrollment in the GALE-401, or Anagrelide Controlled Release, Phase 2 Clinical Trial. The Phase 2, clinical proof-of-concept study is treating 18 patients with elevated platelet counts in myeloproliferative neoplasms, or MPNs, including Essential Thrombocythemia, or ET, Polycythemia Vera, or PV, and Primary Myelofibrosis, or PMF. The Phase 2 trial is an open-label, single-arm, multicenter study designed to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure plasma concentrations of anagrelide. The platelet lowering ability of GALE-401 will be measured by the proportion of patients that achieve a complete or partial platelet response for at least four weeks during 24 weeks of treatment. With enrollment complete, patients will now be followed for platelet response while they continue study treatment.
November 13, 2014
16:21 EDTARGSArgos Therapeutics reports Q3 EPS (77c), consensus (55c)
Subscribe for More Information
November 11, 2014
09:33 EDTGNBTGenerex Biotech presents results of HER2 antibody response
Generex Biotechnology announced a presentation showing that induction of an antibody response to the HER2 target of its AE37 cancer vaccine correlated with a reduction of relapse in breast cancer patients. The AE37 cancer vaccine is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. The presentation was part of the 29th Annual Meeting & Associated Programs of the Society for Immunotherapy of Cancer that was held November 6-9, 2014 in National Harbor, MD. The presentation, entitled "Correlation of HER2/neu antibody response to clinical response in a phase II trial of the AE37+GM-CSF HER2 peptide vaccine" by Greene et al, further expands the evidence showing that the immunological response generated by the Company's novel cancer immunotherapeutic correlates with effectiveness. In particular, the study showed that the level of induction of the antibody response rather than absolute levels of HER2-specific antibodies was higher in patients who did not relapse. While cellular immune responses have been consistently demonstrated in clinical trials of AE37, this is the first study to characterize the generation of HER2-specific antibody responses elicited by the AE37 vaccine. The AE37 cancer vaccine was designed to specifically activate HER2-specific CD4+ T cells. This cell type is important both in the induction of both cellular and antibody immune responses. In addition to the induction of HER2-specific CD4+ T cells, CD8+ cytotoxic T lymphocytes induction also been shown in immunized patients. Interestingly, a reduction of immune suppressive T regulatory cells has also been consistently shown in AE37 immunized patients.
09:17 EDTGALEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FMSA Holdings (FMSA), up 4.7% following third quarter results. ALSO HIGHER: AVEO Pharmaceuticals (AVEO), up 7.6% after entering agreement with Ophthotech (OPHT) to license tivozanib... Ophthotech is 2.1% higher in pre-market trading... Galena Biopharma (GALE), up 3.6% after first patient dosed in NeuVax and Herceptin combination Phase 2 trial... Yamana Gold (AUY), up 3% after being upgraded to Overweight from Neutral at HSBC... Ambac Financial (AMBC), up 3.1% after being upgraded to Neutral from Sell at MKM Partners... China Finance (JRJC), up 12.4% after announcing a new partnership with Great Wall Securities... Zynga (ZNGA), up 5.7% after being upgraded on mobile business growth at Jefferies... Fiat Chrysler (FCAU), up 2.2% after being initiated with a Conviction Buy at Goldman. DOWN AFTER EARNINGS: Applied Optoelectronics (AAOI), down 10.7%... Ekso Bionics (EKSO), down 2.2%. ALSO LOWER: Alibaba Group (BABA), down 1.6% following comments made by vice chairman Joseph Tsai in an interview.
07:06 EDTGALEGalena doses first patient in NeuVax, Herceptin combination Phase 2 trial
Subscribe for More Information
November 10, 2014
13:18 EDTGALEGalena terminates Brian Hamilton as Chief Medical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use